Literature DB >> 19956530

Prognostic factors in non-Hodgkin's lymphoma patients treated by autologous stem cell transplantation: a single center experience.

Cheolwon Suh1, Sang Hee Kim, Hyo Jung Kim, Geundoo Jang, Eun Kyung Kim, Ok Bae Ko, Shin Kim, Hee Jung Sohn, Jung Shin Lee, M Wookun Kim, Jooryung Huh.   

Abstract

PURPOSE: Autologous stem cell transplantation (ASCT) is increasingly used in patients with non-Hodgkin's lymphoma (NHL). Various clinical parameters-were evaluated to obtain significant predictors of the outcome following ASCT in patients with NHL.
MATERIALS AND METHODS: Between April 1994 and December 2003, ASCT was performed on 80 patients with NHL at the Asan Medical Center.
RESULTS: Patients had various histological subtypes and disease status. The two year progression free survival (PFS) and overall survival for all patients were 34 and 31%, respectively. A univariate analysis showed the performance status, stage, modified extranodal involvement category, International Prognostic Index (IPI) at mobilization, disease status at mobilization, and history of radiation prior to mobilization as significant predictors of the outcome following ASCT. Four risk groups, with different 2 year PFS, were identified by the age adjusted IPI at mobilization (mAAIPI): low risk 44%; low intermediate risk 40%; high intermediate risk 19%; and high risk 0% (p=.0003). A multivariate analysis revealed 3 significant factors for the PFS: disease status, prior RT and mAAIPI.
CONCLUSION: The mAAIPI was found to be an independent predictor of the outcome of NHL patients undergoing ASCT. This powerful prognostic tool should be used to evaluate potential candidates for ASCT.

Entities:  

Keywords:  Autologous peripheral blood stem cell transplantation; Hematopoietic stem cell mobilization; Non-Hodgkin's lymphoma; Prognosis

Year:  2005        PMID: 19956530      PMCID: PMC2785926          DOI: 10.4143/crt.2005.37.5.294

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  20 in total

Review 1.  International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.

Authors:  M A Shipp; M D Abeloff; K H Antman; G Carroll; A Hagenbeek; M Loeffler; E Montserrat; J A Radford; G Salles; N Schmitz; M Symann; J O Armitage; T Philip; B Coiffier
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

2.  The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation.

Authors:  G L Phillips; J W Fay; R H Herzig; H M Lazarus; S N Wolff; H S Lin; D C Shina; G P Glasgow; R C Griffith; C W Lamb
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

3.  Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle.

Authors:  F B Petersen; F R Appelbaum; R Hill; L D Fisher; C L Bigelow; J E Sanders; K M Sullivan; W I Bensinger; R P Witherspoon; R Storb
Journal:  J Clin Oncol       Date:  1990-04       Impact factor: 44.544

4.  The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.

Authors:  C H Moskowitz; S D Nimer; J R Glassman; C S Portlock; J Yahalom; D J Straus; J P O'Brien; N Elkin; J R Bertino; A D Zelenetz
Journal:  Bone Marrow Transplant       Date:  1999-03       Impact factor: 5.483

5.  Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors.

Authors:  A P Rapoport; R Lifton; L S Constine; R E Duerst; C N Abboud; J L Liesveld; C H Packman; S Eberly; R F Raubertas; B A Martin; W R Flesher; P A Kouides; J F DiPersio; J M Rowe
Journal:  Bone Marrow Transplant       Date:  1997-05       Impact factor: 5.483

6.  High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

Authors:  J M Vose; J R Anderson; A Kessinger; P J Bierman; P Coccia; E C Reed; B Gordon; J O Armitage
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

7.  The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.

Authors:  J Blay; F Gomez; C Sebban; T Bachelot; P Biron; C Guglielmi; A Hagenbeek; R Somers; F Chauvin; T Philip
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

Authors:  T Philip; J O Armitage; G Spitzer; F Chauvin; S Jagannath; J Y Cahn; P Colombat; A H Goldstone; N C Gorin; M Flesh
Journal:  N Engl J Med       Date:  1987-06-11       Impact factor: 91.245

10.  International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades.

Authors:  J Hermans; A D Krol; K van Groningen; P M Kluin; J C Kluin-Nelemans; M H Kramer; E M Noordijk; F Ong; P W Wijermans
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more
  1 in total

1.  Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement.

Authors:  Ock Bae Ko; Geundoo Jang; Shin Kim; Jooryung Huh; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2008-12       Impact factor: 2.884

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.